. "5"^^ . "JAMASPISHVILI, Tamar" . "Role of urine markers in prostate cancer diagnostics"@en . "Gal\u00E9n" . "5"^^ . "978-80-7262-450-8" . . "Role of urine markers in prostate cancer diagnostics"@en . . "Role mo\u010Dov\u00FDch marker\u016F v diagnostice karcinomu prostaty" . . "[43D4C2829E3D]" . "RIV/61989592:15110/11:10225051" . . "\u0160TUDENT, Vladim\u00EDr" . . . "KOL\u00C1\u0158, Zden\u011Bk" . . "Role mo\u010Dov\u00FDch marker\u016F v diagnostice karcinomu prostaty"@cs . . "15110" . . "Role mo\u010Dov\u00FDch marker\u016F v diagnostice karcinomu prostaty" . "BOUCHAL, Jan" . "Praha" . . "Praha" . "RIV/61989592:15110/11:10225051!RIV12-MZ0-15110___" . . . "KR\u00C1L, Milan" . . . "Role mo\u010Dov\u00FDch marker\u016F v diagnostice karcinomu prostaty"@cs . . . . "227405" . "2011-11-23+01:00"^^ . . . "urine markers; prostate carcinoma"@en . "2"^^ . "Diagnostika karcinomu prostaty je zalo\u017Eena na histologick\u00E9m pr\u016Fkazu onemocn\u011Bn\u00ED zpravidla z punk\u010Dn\u00ED biopsie prostaty. Indikac\u00ED je elevace v\u011Bkov\u011B specifick\u00E9ho PSA \u010Di suspektn\u00ED rekt\u00E1ln\u00ED n\u00E1lez. K indikaci rebiopsie prostaty n\u00E1s pak vede nejen trvaj\u00EDc\u00ED podez\u0159en\u00ED p\u0159i rekt\u00E1ln\u00EDm vy\u0161et\u0159en\u00ED, setrvale vysok\u00E9 \u010Di progreduj\u00EDc\u00ED PSA, ale tak\u00E9 v\u00FDt\u011B\u017Enost a efektivita pou\u017Eit\u00ED mo\u010Dov\u00FDch onkomarker\u016F na karcinom prostaty, kter\u00E9 se v posledn\u00ED dob\u011B p\u0159esouvaj\u00ED z laboratorn\u00EDch podm\u00EDnek do klinick\u00E9 praxe. C\u00EDlem pr\u00E1ce je vytvo\u0159en\u00ED metodiky vy\u0161et\u0159ov\u00E1n\u00ED mo\u010Dov\u00FDch marker\u016F pro karcinom prostaty (PCA3, AMACR, MSMB a TRPM8) a jejich vyu\u017Eit\u00ED v b\u011B\u017En\u00E9 klinick\u00E9 praxi. Na souboru pacient\u016F se poda\u0159ilo vytvo\u0159it metodiku vy\u0161et\u0159ov\u00E1n\u00ED mo\u010Dov\u00FDch onkomarker\u016F pro karcinom prostaty. Nejvy\u0161\u0161\u00ED v\u00FDt\u011B\u017Enosti jsme dos\u00E1hli p\u0159i sou\u010Dasn\u00E9m pou\u017Eit\u00ED \u010Dty\u0159 onkomarker\u016F, \u010D\u00EDm\u017E stoup\u00E1 validita predikce p\u0159\u00EDtomnosti karcinomu prostaty a podporuje tak rozhodov\u00E1n\u00ED p\u0159i indikaci rebiopsi\u00ED prostaty zejm\u00E9na u pacient\u016F s PSA v rozmez\u00ED 3-15 ng/ml."@cs . "Vybran\u00E9 ot\u00E1zky onkologie XV." . "P(GD303/09/H048), P(NS9940), Z(MSM6198959216)" . "Diagnostika karcinomu prostaty je zalo\u017Eena na histologick\u00E9m pr\u016Fkazu onemocn\u011Bn\u00ED zpravidla z punk\u010Dn\u00ED biopsie prostaty. Indikac\u00ED je elevace v\u011Bkov\u011B specifick\u00E9ho PSA \u010Di suspektn\u00ED rekt\u00E1ln\u00ED n\u00E1lez. K indikaci rebiopsie prostaty n\u00E1s pak vede nejen trvaj\u00EDc\u00ED podez\u0159en\u00ED p\u0159i rekt\u00E1ln\u00EDm vy\u0161et\u0159en\u00ED, setrvale vysok\u00E9 \u010Di progreduj\u00EDc\u00ED PSA, ale tak\u00E9 v\u00FDt\u011B\u017Enost a efektivita pou\u017Eit\u00ED mo\u010Dov\u00FDch onkomarker\u016F na karcinom prostaty, kter\u00E9 se v posledn\u00ED dob\u011B p\u0159esouvaj\u00ED z laboratorn\u00EDch podm\u00EDnek do klinick\u00E9 praxe. C\u00EDlem pr\u00E1ce je vytvo\u0159en\u00ED metodiky vy\u0161et\u0159ov\u00E1n\u00ED mo\u010Dov\u00FDch marker\u016F pro karcinom prostaty (PCA3, AMACR, MSMB a TRPM8) a jejich vyu\u017Eit\u00ED v b\u011B\u017En\u00E9 klinick\u00E9 praxi. Na souboru pacient\u016F se poda\u0159ilo vytvo\u0159it metodiku vy\u0161et\u0159ov\u00E1n\u00ED mo\u010Dov\u00FDch onkomarker\u016F pro karcinom prostaty. Nejvy\u0161\u0161\u00ED v\u00FDt\u011B\u017Enosti jsme dos\u00E1hli p\u0159i sou\u010Dasn\u00E9m pou\u017Eit\u00ED \u010Dty\u0159 onkomarker\u016F, \u010D\u00EDm\u017E stoup\u00E1 validita predikce p\u0159\u00EDtomnosti karcinomu prostaty a podporuje tak rozhodov\u00E1n\u00ED p\u0159i indikaci rebiopsi\u00ED prostaty zejm\u00E9na u pacient\u016F s PSA v rozmez\u00ED 3-15 ng/ml." . . . "Diagnostics of prostate cancer (PCa) is based on histologic evidence of the disease from prostate biopsy. Indication for prostate biopsy are age specific PSA elevation or abnormal digital rectal examination (DRE). Indication for rebiopsy are persistent suspicion on DRE, elevated PSA or its further progression. Helpful are also urine oncomarkers for PCa which are transferred from laboratory settings to clinical practice. Aim of the study was preparing methodics for prostate cancer urine markers examination (PCA3, AMACR, MSMB a TRPM8) and their application in clinical practice. On set of patients we prepared metodics for PCa urine markers examination. The best efficacy was reached when quadriplex model of oncomarkers was used. So the predictivity of PCa presence increases and supports decision making in rebiopsy indication especially in men with PSA range 3-15 ng/ml."@en . .